Pulmonary vein leiomyosarcoma

Summary

Pulmonary vein leiomyosarcoma (MONDO:0004206) is a disease. A subtype of vein disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pulmonary vein leiomyosarcoma
Mondo ID	MONDO:0004206
DOID	DOID:7388
NCIT	C5374
UMLS	C1335575
MedGen	235513
GARD	0023875
Anatomy (UBERON)	UBERON:0002016
Is cancer (heuristic)	no

Also known as: leiomyosarcoma of pulmonary vein · leiomyosarcoma of the pulmonary vein · pulmonary vein leiomyosarcoma

Disease family

This is a subtype of vein disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › vein disorder › pulmonary vein leiomyosarcoma

Related subtypes (12): venous insufficiency, portal vein thrombosis, occlusion of tributary of retinal vein, central retinal vein occlusion, cavernous sinus meningioma, superior vena cava angiosarcoma, phlebitis, malignant jugulotympanic paraganglioma, varicose disease, vein of Galen aneurysm, isolated splenic vein thrombosis, isolated mesenteric vein thrombosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.